Outsourcing

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Employing novel technologies and more patient-centric approaches can help to reduce the potential of formulation failure.

Integrating Strategies for Formulation Success

CordenPharma’s partnership with GENEPEP expedites lead development and validation in project phases, and its LNP β-sitosterol supports sustainable emission reduction targets.

CordenPharma Leverages Peptide Drug Discovery and Development with GENEPEP and Works on Reducing Emissions

Daniel Radiloff, PhD, is director of Business Development, Pacific BioLabs.

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

Matthew Hewitt is vice-president, technical officer, Cell & Gene Therapy & Biologics, at Charles River Laboratories.

Larry Bellot, PhD, is scientific advisor, Cell and Gene Therapy, at Charles River Laboratories.

Chad Andersen is associate director, Manufacturing Sciences & Technology, at Charles River Laboratories.

A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.

Best Practice Tech Transfer Methods for CGTs

The new centralized hub will provide advanced testing of nucleic acids, which is expected to simplify mRNA substance testing.

TriLink BioTechnologies Launches Analytical Sciences Center of Excellence

The 65,000-square-foot facility is designed with the capacity and capability to help scale the next generation of CGTs for human trials and beyond. 

eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities 

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing. 

ten23 Expands Sterile Manufacturing Capacity at VIVA 1 Facility 

WuXi XDC will provide end-to-end services to support Boostimmune’s discovery of novel bioconjugates.

WuXi XDC, Boostimmune Sign MOU

The facility is based on a state-of-the-art design concept that allows maximum flexibility for a multi-product, multi-platform offering.

Aurigene Pharmaceutical Services Expands with New Facility 

The new portfolio from the acquisition will include contract research organization solutions, contract development and manufacturing organization solutions, and KSM/API solutions.

Contract Development Services